Last reviewed · How we verify

NCT02967640

Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?

Completed Phase 2, PHASE3 Last updated 22 August 2025
What this trial tests

Phase 2, PHASE3 trial testing Ketalar in Rotator Cuff Tendinitis in 14 participants. Completed in 30 December 2024.

Timeline
30 May 2018
Primary endpoint
30 December 2024
30 December 2024

Quick facts

Lead sponsorHelse Møre og Romsdal HF
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingdouble
Primary purposetreatment
Enrollment14
Start date30 May 2018
Primary completion30 December 2024
Estimated completion30 December 2024
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Helse Møre og Romsdal HF — full company profile →

Who can join

40 and older, any sex, with Rotator Cuff Tendinitis or Chronic Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The hypothesis of the present study is that in patients with rotator cuff tendinopathy a specific pharmacological blocking of peripheral glutamate-receptor N-methyl-d-aspartate receptor type1 (NMDAR) glutamate receptors will result in pain alleviation. Activated NMDAR1 has been demonstrated to be crucial for pain regulation in various pain disorders, and in biopsies from patients with tendinopathy, NMDAR1 was found to be activated. To test this hypothesis a specific NMDA receptor antagonist, ketalar (ketamine), will be injected guided by ultrasound into the subacromial space in patients with rotator cuff tendinopathy, and subsequently the pain response will be assessed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ketalar

Trials testing the same drug.

Other recruiting trials for Rotator Cuff Tendinitis

Currently open trials in the same condition.

Other Helse Møre og Romsdal HF trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02967640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing